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INTRAVENOUS injection of bacillus
Calmette-Guerin (B.C.G.) organisms sup-
presses growth of artificial pulmonary
metastases of rat sarcomata, produced by
intravenous injection of tumour cells
(Baldwin and Pimm, 1973a). In addition,
spontaneous pulmonary metastases,
appearing after surgical removal of sub-
cutaneous growths of a transplanted rat
epithelioma, are restricted by intraven-
ously administered B.C.G. (Baldwin and
Pimm, 1973b). This type of growth sup-
pression is probably areflection ofa B.C.G.
mediatedgranulomatousresponseatthesite
oftumourmetastasisfollowingB.C.G. entry
into lung tissue and may be comparable
with the restriction oftumourgrowthwhen
cells are injected subcutaneously or intra-
dermally in contact with B.C.G. (Baldwin
and Pimm, 1971, 1973c; Bartlett, Zbar
and Rapp, 1972; Zbar, Bernstein and Rapp
1971).
So far, B.C.G. treatment ofpulmonary
metastasis has been evaluated with trans-
planted animal tumours; the objective
of the present experimental studies was to
assess the influence of intravenously
administered B.C.G. on the development
of metastases in animals bearing primary
tumours, since this approximates more
closely to the clinical situation. In these
experiments rats with primary hepato-
mata, induced by oral administration of
4-dimethylaminoazobenzene, have been
examined for pulmonary metastases and
the influence of intravenously administ-
ered B.C.G. on their development studied.
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MATERIALS AND METHODS
Tumours. Primary hepatomata were
induced by feeding adult male Wistar
rats on a low protein diet containing 0 06%
(w/w) 4-dimethylaminoazobenzene for 90
days (Baldwin, 1964), after which they were
returned to Oxoid cubed diet. The majority
of tumours ultimately appearing in these
rats are classified histologically as hepato-
cellular carcinomata.
Bacillus Calnmette-Gue'rin. Freeze dried
B.C.G. vaccine (Percutaneous) was supplied
by Glaxo Laboratories Ltd, Greenford,
Middlesex. On reconstitution in water the
vaccine contained 10 mg moist weight/ml
of organisms.
Method oftreatment.-After removal from
the carcinogen diet, the rats were treated by
intravenous injections of B.C.G. (1.0-1-5 mg
moist weight) administered into a lateral tail
vein.
Assessment of survical and pulmonary
metastases.-Animals were killed individually
when distressed due to the development of
primary hepatomata. Survivals were calcu-
lated with respect to the initiation of carci-
nogen feeding. The mean survival of B.C.G.
treated rats was compared with that of
untreated controls, and the significance
of the difference assessed by Student's " t
test.
Lungs were examined for metastases by
perfusion with dilute India ink (Wexler,
1966) and the number of macroscopically
detectable surface metastases counted with
a x 10 stereoscopic microscope. The signifi-
cance of the difference in incidence and
numbers of metastases, between treated and
controlgroups was calculated bythe Wilcoxon
non-parametric rank test.R. W. BALDWIN AND M. V. PIMM
RESULTS
The effect of intravenous injection of
B.C.G. on the development of primary
hepatomata and pulmonary metastases
is shown in the Table. In the first experi-
ment, untreated rats survived from 103
to 209 days (mean 152 ± 5*7 days), and
all (17/17) were killed because of primary
hepatomata. Analysis of pulmonary
metastases detectable on the lung surface
of these animals showed that 12/17 (700o)
had visible tumour deposits (1-70 nodules/
lung). The survivals (1 1-209 days, mean
154 ± 7-8 days) of rats treated by 2
intravenous injections of B.C.G. on Days
97 and 111 were comparable with the
control group (P 0.45), and all (14/14)
of these treated rats when killed had
primary hepatomata. However, only 5/14
(35%) of these rats had detectable
pulmonary metastases (1-3 nodules/lung).
Compared with control animals, this
reduction in both the proportion of rats
with metastases and their numbers was
statistically significant (P < 0.05).
In the second experiment, there was a
similar reduction in the incidence and
extent of pulmonary metastases in rats
receiving B.C.G. treatment. Control rats
survived for 1 5-192 days (mean 154 ± 4 3
days) and all developed hepatomata. Of
these, 10/20 (50%o) were found to have
lung surface pulmonary metastases (2-35
nodules/lung). AllratstreatedwithB.C.G.
also developed hepatomata and their
survival (115-178 days, mean 158 ± 3-4
days) was comparable with control rats
(P- 020). However, only 6/19 (32%)
had pulmonary metastases, with 1-17
nodules/lung, a significant reduction
(P 0.05) compared with control animals.
DISCUSSION
Previous studies have demonstrated
that artificially produced or spontaneous
metastases of transplanted rat tumours
are suppressed by intravenous B.C.G.
injection (Baldwin and Pimm, 1973a, b).
In these studies, however, conditions
under which treatment was successful
were not suitable models for a clinical
situation. For example, in the produc-
tion ofartificial metastases by intravenous
injection of tumour cells (Baldwin and
Pimm, 1973a) the number of cells and the
time of initial entry into the lungs are
known precisely and therefore are not
comparable with the probable continued
release of potentially metastatic cells
from a growing primary tumour. Even
with a rat epithelioma, where after
subcutaneous graft excision intravenous
B.C.G. reduces the numbers ofmetastases
(Baldwin and Pimm, 1973b), the initial
tumour graft from which these metastases
originated was present for only a few days.
Neither of these experimental systems
has allowed an evaluation of the influence
of B.C.G. on metastases when the animal
TABLE.-Infiuence ofIntravenously Administered B.C.G. on Growth and Metastasis
ofPrimary Rat Hepatornata
Intravenous
B.C.G. treatment
Dose
(mg moist
Expt weight) Day*
1 2x1 5 97, 111
Mean survival
Days±s.e. P
154±7-8 0 45
152±57 7
2 2x1 0 97, 111 158±3-4 0-20
- 154±43
No. rats
with
hepatomata
14/14
17/17
19/19
20/20
Pulmonary metastases
No. rats
with
metastases No. nodules/lung
5/14 9xO, 3xl, 2, 3
12/17 5xO, 1, 3x2, 2x4,
10, 2x11, 13, 23, 70
6/19 13xO, 3x1, 2x2,
17
10/20 lOxO, 2x2, 3, 4, 6,
2x20, 23, 32, 35
* With respect to initiation of carcinogen feeding (Days 0-90).
p
<0 05
0 05
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has an initial, localized, progressively
growing tumour.
The present studies extend these
previous observations and demonstrate
that pulmonary metastases from primary
rat hepatomata can be significantly res-
tricted by intravenous B.C.G. injection.
In these tests, treatment had no influence
on the occurrence of primary tumours or
their growth rates as assessed from the
survival of the animals. Most impor-
tantly, however, treatment of metastases
was effective in the presence of primary
tumours.
Clinically,suppressionoftumourgrowth
by contact with B.C.G. organisms has
been achieved with surface tumours,
particularly melanoma (Morton et al.,
1970), where intralesional infiltration of
B.C.G. induces regression. Present and
previous experimental studies suggest
that tumour deposits at other sites, and
particularly pulmonary metastases, might
be controlled by infiltration ofB.C.G. into
the site of tumour or metastatic deposits.
Moreover, it has recently been shown in a
small number of cases that the survival
of dogs with osteosarcoma is significantly
increased if B.C.G. is administered intra-
venously post amputation of the affected
limb (Owen et al., personal communica-
tion). However, toxic reactions to B.C.G.
may result following intravenous adminis-
tration. These include the formation of
granulomatous lesions, particularly in the
liver causing hepatic dysfunction, and a
generalized systemic infection with B.C.G.
organisms (Sparks et al., 1973; Hunt et al.,
1973). Non-living and non-toxic myco-
bacterial preparations will therefore be
needed before B.C.G. could be used
clinically, as described in the experimental
situation in this paper. For treatment of
transplanted rat tumours, B.C.G. steri-
lized by y irradiation retains suppressive
properties both at local subcutaneous
sites and for controlling pulmonary meta-
stases (Baldwin et al., 1974). In addition,
B.C.G. cell walls attached to oil droplet
emulsions can restrict localized tumours
(Zbar, Rapp and Ribi, 1972) and the
development of pulmonary metastases
(Baldwin and Pimm, 1973d). The use
of these B.C.G. preparations clinically
would remove thepossibility ofgeneralized
B.C.G. infection from this type of treat-
ment. Other non-living mycobacterial
preparations, such as methanol extracted
residue (Weiss, Bonhag and Leslie, 1966)
and delipidated mycobacterial cell walls
(Chedid et al., 1973) should be evaluated
for this type of tumour suppressive
property so that treatment of metastases,
particularly in the lung, could be feasible
clinically as well as in the type of experi-
mental situation described in this paper.
This work was supported by the Cancer
Research Campaign. We thank Glaxo
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